Research

At the start of May, we posted an update on clinical trials that were evaluating high dose biotin as a treatment for multiple sclerosis. Undertaken by biotechnology company, medDay, the results of these trials...

Research summary:  Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor The...

INTERVIEW WITH DR LEIGH CHARVET – NYU LANGONE MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER BD: Brett Drummond, MStranslate LC: Dr. Leigh Charvet, NYU Langone Multiple Sclerosis Comprehensive Care...

INTERVIEW WITH DR CHRISTIAN GRUBER – MEDICAL UNIVERSITY OF VIENNA AND UNIVERSITY OF QUEENSLAND BD: Brett Drummond, MStranslate CG: Dr. Christian Gruber, Medical University of Vienna & University...

At the recent American Academy of Neurology (AAN) conference, MedDay provided an update on their trials into the use of their biotin compound (MD1003) as a treatment for multiple sclerosis (MS). In...

By Brett Drummond When we talk about basic science discoveries related to multiple sclerosis, we often finish the article by explaining that this finding is likely to be 5-10 years away from potentially...

AMERICAN ACADEMY OF NEUROLOGY (AAN) MEETING 2016 INTERVIEW WITH DR REBECCA SPAIN – OREGON HEALTH AND SCIENCES UNIVERSITY (OHSU), VA PORTLAND HEALTH CARE SYSTEM BD: Brett Drummond,...

AMERICAN ACADEMY OF NEUROLOGY (AAN) MEETING 2016 INTERVIEW WITH DR TOMAS KALINCIK – MELBOURNE BRAIN CENTRE, ROYAL MELBOURNE HOSPITAL BD: Brett Drummond, MStranslate TK: Dr Tomas Kalincik,...

A small, Phase II clinical trial has shown that a common over the counter antihistamine, called clemastine fumarate, has the ability to partially reverse damage to the optic nerve in people with multiple...

Research Summary: Conditioned Medium from the Stem Cells of Human Exfoliated Deciduous Teeth Ameliorates Experimental Autoimmune Encephalomyelitis The background Current MS therapies mostly work to suppress...